Imipenem

Manufactured by AK Scientific

Sourced in United States

Imipenem is a broad-spectrum antibiotic that belongs to the carbapenem class. It is used as a laboratory standard for testing the antimicrobial susceptibility of bacteria.

Automatically generated - may contain errors

Lab products found in correlation

Aztreonam, by AK Scientific (1 mentions) Ceftazidime, by Chem-Impex (1 mentions) Cefepime, by Chem-Impex (1 mentions) Methanol, by Thermo Fisher Scientific (1 mentions) Formic acid, by Merck Group (1 mentions) Aztreonam, by Chem-Impex (1 mentions) Meropenem, by AK Scientific (1 mentions)

2 protocols using imipenem

Time-Kill Assay of Pan-Resistant Klebsiella

Check if the same lab product or an alternative is used in the 5 most similar protocols

For all experiments, fresh Muller–Hinton Broth (MHB) (Difco, Detroit, MI, USA) was used. Total bacterial counts were determined by plating samples on Muller-Hinton agar (MHA) (Difco, Detroit, MI, USA) followed by incubation at 37 °C for 24 h. This study utilized an unusual pan resistant Klebsiella pneumoniae, that was isolated from a hip abscess of a U.S. patient (BioProject PRJNA391323, GenBank Accession number: CP022125.1-CP022128.1)¹². Previous characterization of this isolate has shown that it harbors four known beta lactamase genes, including plasmid-mediated bla_NDM-1 and bla_CMY-6, as well as chromosomal bla_CTX-M-15 and bla_SHV-2. This strain was found to be non-susceptible to a range of drugs tested, including all beta-lactams, colistin, and tigecycline. For time- kill assays, fresh drug stocks of aztreonam and imipenem (AKScientific, Union City, CA, USA) were used at clinically relevant concentrations.

Kaur J.N., Singh N., Smith N.M., Klem J.F., Cha R., Lang Y., Chen L., Kreiswirth B., Holden P.N., Bulitta J.B, & Tsuji B.T. (2024). Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae. Scientific Reports, 14, 3148.

+ Open protocol

+ Expand

Carbapenem-resistant Enterobacterales Permeability

Check if the same lab product or an alternative is used in the 5 most similar protocols

One carbapenem-resistant clinical isolate each of K. pneumoniae (KP3800) and E. cloacae (EC3800) were used for all OM permeability studies. Two additional K. pneumoniae isolates (KP6478 and KP6484) were used for additional OM permeability studies to further support the developed assay and obtain insights on strain-to-strain variability. Imipenem and meropenem were purchased from AK Scientific (Union City, CA). Ceftazidime, cefepime, aztreonam, and PAβN were obtained from Chem-Impex International (Wood Dale, IL). Water and methanol (both LC/MS grade) were purchased from Fisher Scientific (Fair Lawn, NJ). Formic acid was acquired from Sigma-Aldrich (St. Louis, MO). Bacteria were grown in cation-adjusted Mueller-Hinton broth (MHII; BD BBL, Sparks, MD), and agar MICs (14 (link)) were determined according to CLSI guidelines (14 (link), 36 ).
To predict the clinically relevant range of β-lactam concentrations, we performed Monte Carlo simulations to calculate the average unbound concentration at steady state in critically ill patients at the highest clinical dose (5 (link)). These simulations were performed for a continuous infusion and based on a literature review for the pharmacokinetics of each compound (Imipenem [37 (link)– (link)40 (link)], meropenem [41 (link)– (link)45 (link)], cefepime [46 (link)], Ceftazidime [47 (link), 48 (link)], and aztreonam [38 (link), 49 (link)]).

Kim T.H., Tao X., Moya B., Jiao Y., Basso K.B., Zhou J., Lang Y., Sutaria D.S., Zavascki A.P., Barth A.L., Reeve S.M., Schweizer H.P., Deveson Lucas D., Boyce J.D., Bonomo R.A., Lee R.E., Shin B.S., Louie A., Drusano G.L, & Bulitta J.B. (2020). Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae. mBio, 11(1), e03189-19.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!